

18 May 2022

Clinical Study Protocol
NGLU-CL06

EudraCT Number: 2015-000753-20

Protocol Title: A Phase I/II open label study in MPS IIIB subjects to investigate the safety, biodistribution, pharmacokinetics, and pharmacodynamics/efficacy of SBC-103 administered intravenously

The global end of trial for study NGLU-CL06 occurred on 02 Nov 2016. This study has not been initiated and therefore no participants were enrolled. No clinical study report was developed.

DocuSigned by:
Patricia Nowowieski
 Signer Name: Patricia Nowowieski
Signing Reason: I approve this document
Signing Time: 18-May-2022 | 17:53:52 EDT
0D339BCB740C49018A8318346A68471D

Exec Dir, Global Franchise CPL Head

Alexion Pharmaceuticals Inc.